As Aaditya watches a cartoon show on television, his right hand wavering to caress soft toys (SpongeBob SquarePants and Noddy) tucked next to him in bed, the boy has no clue that researchers and doctors across the world are watching his recovery with bated breath.
That’s because this frail boy, who is set to turn eight next month, is the first ever to receive a stem cell transplant for a rare and destructive illness — called Childhood Alzheimer’s (medical term: Niemann-Pick Type C or NPC), which causes neurological degeneration and seizures — for which there is no conventional treatment. Stem
Image via Wikipedia
The hardship’s focus is on pilot studies conducted in China. Sean Hu, CEO and Chair of Shenzhen Beike Biotechnologies Co. Ltd. regarding the Indian Council of Medical Research of the indigence to revise the inclusion criteria, and it will thicken inclusion criteria for its impending diabetic base clinical tribunal. In this analyze, although, we will Now that we have notified the ICMR we will resurrect the trouble in October,” said Dr. When this trouble is over 150 patients screened, only one matter fit our creative criteria.” He went onto hint that diabetic bottom disease experienced in a
The rising cost of healthcare has been a cause of concern around the globe. The global economic crisis has seen governments such as the US and Japan attempting to minimise the cost of state-funded healthcare.
The increased prevalence of cardiovascular disorders, metabolic diseases, cancer, etc coupled with the emergence of more virulent forms of existing diseases poses a challenge for current medical therapies.
India is already seen as the world’s low-cost pharmacy as far as conventional therapies are concerned. And the recent economic and epidemiological changes present a lucrative opportunity for the Indian biotech industry to replicate this success in the